Amity Institute of Molecular Medicine and Stem Cell Research JRF Recruitment – Applications Invited

[ad_1]

“Amazing Opportunity: Join the Cutting-Edge Research at Amity Institute of Molecular Medicine and Stem Cell Research as a JRF!”

Amity AIMMSCR Biotech Research Fellow Job – Apply Now

Job Posting: Junior Research Fellow

Advertisement Date: 10-01-2024

Name of the Research Project: “Role of HDAC6 in Regulating Plasticity and Function of M2 Tumor-Associated Macrophages: A Potential Therapeutic Approach to Modulate Chemoresistance in Breast Cancer”

Name of the Post: Junior Research Fellow

Number of Posts: 01

Sponsoring Agency: DST-SERB

Duration of Position: 3 years

Fellowship / Monthly Compensation: INR 35,960/- per month (31,000/- + 4960/ (HRA)) for the first two years, and INR 40,600/- per month (35,000/- + 5600/-(HRA)) for the third year

Essential Qualifications:

M.Tech or M.Sc. in Biotechnology/Biochemistry/Life Sciences from a recognized university with 60% marks or equivalent CGPA. Candidates having a valid CSIR/UGC-NET/GATE score or other national-level exams, along with prior research experience in animal cell culture techniques, molecular biology techniques, and animal handling, will be preferred.

Age Limit:

28 years

  • Appointment of the applicant will be governed by the terms and conditions of the funding agency, particularly applicable to the said project.
  • Interested candidates should submit their application with details of academic qualifications within 15 days of this advertisement to [email protected]

    , with cc to [email protected].

  • No TA/DA will be paid to the candidates for attending the interview.

Keywords: JRF job, biotech, life sciences, Amity Institute of Molecular Medicine and Stem Cell Research. Amity AIMMSCR Biotech Research Fellow Job – Apply Now. Please ensure you are subscribed to the Getmicrobiologyjobs Times Newsletter and our YouTube channel to be notified of the latest industry news. Follow us on social media like TwitterTelegramFacebook and Instagram.



[ad_2]

Leave a Comment